This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, C-Fms) Inhibitor CT-1578 Demonstrates Ability To Prevent The Onset Of Rheumatoid Arthritis And Potency In Treating And Reversing Bone And Cartilage Damage In Preclinical Models

SEATTLE, Oct. 15, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CT-1578's (previously known as SB-1578) unique kinase spectrum that selectively inhibits JAK2 over JAK1 or JAK3, coupled with its inhibition of FLT-3 and c-Fms, produced potency in not only preventing the development of rheumatoid arthritis ("RA"), but also in its treatment and reversal of bone and joint destruction after the onset of RA in preclinical models according to results published in the October 15, 2012 issue of the Journal of Immunology.

The authors concluded that CT-1578's selective inhibition of JAK2, FLT-3 and c-Fms, which are the three kinases that are critical to the pathogenesis of RA, is unprecedented in the current stable of kinase inhibitors.

"These results support the hypothesis that inhibition of JAK1 and JAK3 is not mandatory for therapeutic benefit in RA," noted Jack W. Singer, M.D., EVP Global Medical Affairs and Translational Medicine at CTI. "The results demonstrate that CT-1578's unique kinase spectrum not only blocks the inflammatory response, but prevents the infiltration of macrophages and neutrophils into affected joints, while inhibiting antigen presenting dendritic cells and the autoimmune component of the disease. These attributes resulted in prevention of joint synovial hyperplasia and bone destruction, that was sufficiently impressive that the Journal of Immunology chose to use images of the results on the cover of the October 15 th issue."

About the Study

In the study, when SB1578 was orally administered in a preclinical model of RA, it demonstrated a reduction of the level of proinflammatory cytokines, which was accompanied by a reduction in joint inflammation. In RA patients, the increase in cytokines correlates with disease progression and joint destruction. In the preclinical model, SB1578 was also effective in reversing an elevation in neutrophils, which play an essential role in the initiation of joint inflammation and damage to bone and cartilage resulting in a mitigation of damage to the joints. Additionally, SB1578 showed the ability to modulate the autoimmune component of RA that is involved in the early development of RA by inhibiting a pathway that leads to the initiation of an inflammatory response. The authors state, "The activities against these three kinases [JAK2, FLT-3 and c-Fms], which play crucial roles in the pathogenesis of arthritis, differentiates SB1578 from other less selective JAK family kinase inhibitors that are in clinical development for rheumatoid arthritis and provides a novel and attractive therapeutic alternative."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs